Can you take Cisapride with Jideytro?
1 drug interaction and 13 additional warnings found for the following 2 drugs:
- cisapride
- Jideytro (zidesamtinib)
Drug interactions
Major drug interactions
Major:
cisapride zidesamtinib
Applies to: cisapride and Jideytro (zidesamtinib)
Cisapride is no longer commercially available in the U.S. You should only take cisapride if you are prescribed the medication through an investigational limited access program and are closely monitored by your doctor.
Using cisapride together with zidesamtinib is not recommended. Combining these medications can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with either of these medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
cisapride Food/Lifestyle
Applies to: cisapride
Cisapride is no longer on the market in the US. Do not take cisapride with any other medication, food, or beverage.
**Cisapride (Propulsid) is no longer marketed in the United States. You should only be taking cisapride if you are obtaining the medication from your doctor though a Limited Access Program developed jointly by the manufacturer and the FDA.**
Major:
zidesamtinib Food/Lifestyle
Applies to: Jideytro (zidesamtinib)
You should not consume grapefruit or grapefruit products while taking this medication as they can increase the blood levels of zidesamtinib in your body, putting you at a higher risk of serious side effects.
These may include:
- effects on the brain and nervous system, such as dizziness, fainting, depression, or problems speaking
- lung problems
- bone fractures
- muscle pain
- inflammation of the pancreas
- a change in the electrical activity of your heart called QT prolongation
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
11 potential interactions Applies to: 11 conditions, including Heart Failure, Osteoporosis, Arrhythmia, Liver Disease, and Long QT Syndrome.
Arrhythmia
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Arrhythmia.
Zidesamtinib can prolong QTc and increase the risk of ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death. Zidesamtinib has not been studied in patients with a history of QTcF greater than 450 msec on more than one assessment prior to initiation. Monitor ECGs and electrolytes before treatment and more frequently in patients with long QT syndrome, clinically significant bradyarrhythmia, or severe/uncontrolled heart failure. Withhold, reduce, or discontinue this drug based on severity.
Cardiovascular Conditions and Disorders
Major:
cisapride
Cisapride has a major potential interaction with Cardiovascular Conditions and Disorders.
The use of cisapride is contraindicated in patients with cardiac disease. Serious cardiac arrhythmias, including ventricular arrhythmias and torsades de pointes associated with QT prolongation have been rarely associated with the use of cisapride, especially when taken in conjunction with other medications known to prolong the QT interval.
Gastrointestinal Hemorrhage
Major:
cisapride
Cisapride has a major potential interaction with Gastrointestinal Hemorrhage.
The use of cisapride is contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation. Enhanced gastrointestinal motility could be harmful in these patients.
Gastrointestinal Obstruction
Major:
cisapride
Cisapride has a major potential interaction with Gastrointestinal Obstruction.
The use of cisapride is contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation. Enhanced gastrointestinal motility could be harmful in these patients.
Gastrointestinal Perforation
Major:
cisapride
Cisapride has a major potential interaction with Gastrointestinal Perforation.
The use of cisapride is contraindicated in patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation. Enhanced gastrointestinal motility could be harmful in these patients.
Heart Failure
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Heart Failure.
Zidesamtinib can prolong QTc and increase the risk of ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death. Zidesamtinib has not been studied in patients with a history of QTcF greater than 450 msec on more than one assessment prior to initiation. Monitor ECGs and electrolytes before treatment and more frequently in patients with long QT syndrome, clinically significant bradyarrhythmia, or severe/uncontrolled heart failure. Withhold, reduce, or discontinue this drug based on severity.
Interstitial Lung Disease
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Interstitial Lung Disease.
Zidesamtinib can cause severe or life-threatening interstitial lung disease or pneumonitis. Monitor for new or worsening pulmonary symptoms. Immediately withhold treatment if ILD/pneumonitis is suspected, and resume at same or reduced dose or permanently discontinue therapy based on severity.
Liver Disease
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Liver Disease.
Zidesamtinib has not been studied in patients with severe liver impairment.
Long QT Syndrome
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Long QT Syndrome.
Zidesamtinib can prolong QTc and increase the risk of ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death. Zidesamtinib has not been studied in patients with a history of QTcF greater than 450 msec on more than one assessment prior to initiation. Monitor ECGs and electrolytes before treatment and more frequently in patients with long QT syndrome, clinically significant bradyarrhythmia, or severe/uncontrolled heart failure. Withhold, reduce, or discontinue this drug based on severity.
Osteoporosis
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Osteoporosis.
Zidesamtinib can increase the risk of skeletal fractures, which occurred in some patients with predisposing factors including osteoporosis, bone metastasis, and age-related degenerative conditions. Promptly evaluate signs or symptoms of fracture during treatment.
Renal Dysfunction
Moderate:
Jideytro
The zidesamtinib in Jideytro has a moderate potential interaction with Renal Dysfunction.
Zidesamtinib has not been studied in patients with severe renal impairment or dialysis.
Report options
More resources
cisapride
A total of 420 drugs are known to interact with cisapride.
- Cisapride is in the drug class GI stimulants.
- Cisapride is used to treat the following conditions:
Jideytro
A total of 415 drugs are known to interact with Jideytro.
- Jideytro is in the drug class multikinase inhibitors.
- Jideytro is used to treat Non Small Cell Lung Cancer.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.